GROSS HEPATIC CHANGES IN DEVELOPING ALBINO RATS EXPOSED TO VALPROIC ACID
AbstractBackground: Valproid Acid (VPA) is a broad spectrum antiepileptic drug. Its use during pregnancyhas been associated with congenital anomalies and hepatotoxicity. This study was designed to assessthe effects of VPA on the gross structure of liver in developing albino rats exposed to the drug duringvarious trimesters of pregnancy. Methods: In this experimental study 40 pregnant rats were dividedinto 4 equal groups A, B, C and D. Group A received VPA in a dose of 500 mg/Kg/day intraperitonealy(I/P) on days 3, 4 and 5 of gestation. Group B received the drug in a dose of 500 mg/Kg/day I/P on days8, 9 and 10 of gestation. Group C received VPA in a dose of 500 mg/Kg/day I/P on days 16, 17 and 18of gestation. Group D received no treatment and was kept as a control group. On day 21, the rats wereeuthanised by cervical dislocation. The liver of the foetuses were dissected out for the assessment oftheir gross structure. Results: Foetal liver of the experimental groups showed significant decrease inweight as well as relative tissue weight index (RTWI) as compared to the control group, although thegross appearance of the foetal liver was normal in all the groups. Conclusion: The use of VPA duringvarious trimesters of pregnancy produces hepatotoxicity in the developing rats. So, the use of this drugduring pregnancy should be carefully decided.Keywords: Valproic acid, Developing albino rats, Hepatotoxicity
Villanueva-Gomez F, Fernandez-Miranda MC. Society, law and
epilepsy. Rev Neurol 2002;35(Suppl 1):S1–S5.
Kammerman S, Wasserman L. Seizure disorder: classification
and diagnosis. West J Med 2001;175:99–103.
Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in
offspring of women with epilepsy. Neurology 2003;60:575–9.
Brodie MJ. Management of epilepsy during pregnancy and
lactation. The Lancet 1990;336:426–7.
Pennel PB. Antiepileptic drug plarmacokinetics during
pregnancy and lactation. Neurology 2003;61:S35–S42.
Devane CL. Pharmacokinetics: drug interactions and Tolerability
of Valproate. Psychopharmacol Bull 2003;37 (Suppl 2):25–42.
Hennry TR. The history of valproate in clinical neuroscience.
Psychopharmacol Bull 2003;37 (Suppl 2):5–16.
Mattson RH, Cramer JA, Collins JF. A comparison of valproate
with carbamazepine for the treatment of complex partial seizures
and secondarily generalized tonic clonic seizures in adults. The
New Eng J Med 1992;327:765–71.
Guirrini R. Valproate as a mainstay of therapy for pediatric
epilepsy. Paediatr Drugs 2006;8:113–29.
Kumar S, Wong H, Yeung SA, Riggs KW, Rurak DW, Abbot
FS, et al. Disposition of valproic acid in maternal, fetal and
newborn sheep 1:Placental transfer, Plasma protein binding and
clearance. Drug Metab Dispos 2000;28(7):845–56.
J Ayub Med Coll Abbottabad 2011;23(2)
Semczuk-sikora A, Semczuk M. Effect of antiepileptic drugs on
human placenta and the fetus. Ginekolpol 2004;75:166–9.
Gopaul S, Farell K, Abbot FS. Effects of age and polytherapy,
risk factors of valproic acid (VPA) hepatotoxicity, in the
excretion of thiol conjugates of (E) –2,4-diene VPA on people
with epilepsy taking VPA. Epilepsia 2003;44:322–8.
MCMahonCL, Braddok SR. Septooptic dysplasia as a
manifestation of valproic acid embryopathy. Teratology
Sadeque AJM, Fisher MB, Korzekwa KR, Gozalez FJ, Rettie
AE. Human cyp2ca and cyp2A6 mediate formation of
Hepatotoxin 4-ene-Valproic acid. JPET 1997;283:689–703.
Driefuss FE, Santilli N, langer DH, Sweeney KP, Moline KA,
Menander KB. Valproic acid hepatic fatalities:a retrospective
review. Neurology 1987;37:379–85.
Cotariu-D, Zaidman JL, Evan S. Neurophysiological and
biochemical changes evoked by valproic acid in the central
nervous system. Prog Neurobiol 1990;34:343–54.
Tong V, chang TK, Chen J, Abbot FS. The effect of valproic acid
on hepatic and palsma levels of 15-F2t-isoprostane in rats. Free
Radic Biol Med 2003;34:1435–46.
Tang W, Polaty J, Abbot FS. Time course of fluorinated valproic
acid in mouse brain and serum and its effect on synaptosomal
aminobutyric acid levels in comparison to valproic acid. Pharm
Exp Therapeut 1997;282:1163–72.
Tong V, Teng XW, Chang TK, Abbot FS. Valproic acid 1: Time
course of lipid peroxidation biomarkers, liver toxicity and valproic
acid metabolite levels in rats. Toxicol Sci 2005;86:425–35.